Alkeus Pharmaceuticals

Alkeus Pharmaceuticals is a clinical-stage biotech advancing an oral investigational therapy, gildeuretinol, designed to address the root cause of retinal degeneration by inhibiting toxic vitamin A dimer formation. The company has active Phase 3 trials (TEASE) in Stargardt disease and a Phase 2/3 trial (SAGA) in geographic atrophy, targeting significant unmet needs in ophthalmology. Led by an experienced team with a track record in rare disease drug development and commercialization, Alkeus is positioned as a potential first-mover in treating Stargardt disease. The company operates as a private, pre-revenue entity with a focused pipeline and a clear mechanistic approach to sight preservation.

Oral deuterated vitamin A analogs designed to inhibit the formation of toxic vitamin A dimers (bisretinoids) in the retina without disrupting the visual cycle.

In Stargardt disease, Alkeus is a potential first-mover with no approved competitors, though other preclinical and clinical approaches exist. In geographic atrophy, it faces established competition from approved complement inhibitors (Syfovre, Izervay) but differentiates itself through its oral route of administration and novel mechanism targeting vitamin A dimerization.